Roles of DNMT3B and PARP1 Genes Expression in Cytogenetically Normal Acute Myeloid Leukemia.

Background: Acute myeloid leukemia (AML) has a heterogeneous molecular profile, clinical presentations, and response to treatments and outcomes. DNA methylation is conducted by DNA methyltransferases including DNMT3B. Poly ADP-ribose polymerase 1 belongs to a family of enzymes that mediate important...

Descripción completa

Detalles Bibliográficos
Publicado en:Clinical Medicine Insights: Oncology pp. 1 - 11
Autores principales: Mahmoud, Hager A, Botros, Shahira KA, Fouad, Abdelhamid Mohamed, Kamel, Mahmoud M, Abdel Aziz, Rania S
Formato: research tables/charts Journal Article
Publicado: Sage Publications Inc. 11/3/2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=180649121&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 180649121
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11795549
        B3KT
      jtl: Clinical Medicine Insights: Oncology
      issn: 11795549
      maglogo: Y
    pubinfo:
      dt: 11/3/2024
      pid: 344
      pub: Sage Publications Inc.
      place: Thousand Oaks, California
    artinfo:
      ui:
        180649121
        180649121
        180649121
        10.1177/11795549241295649
        180649121
      ppf: 1
      ppct: 10
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Roles of DNMT3B and PARP1 Genes Expression in Cytogenetically Normal Acute Myeloid Leukemia.
      aug:
        au:
          Mahmoud, Hager A
          Botros, Shahira KA
          Fouad, Abdelhamid Mohamed
          Kamel, Mahmoud M
          Abdel Aziz, Rania S
        affil: Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt
      sug:
        subj:
          Leukemia, Myeloid, Acute
          Gene Expression
          DNA Methyltransferases
          Egyptians
          Human
          Transferases
          Cytogenetic Analysis
          Polymerase Chain Reaction
          Descriptive Statistics
          Leukocyte Count
          Overall Survival
          Disease-Free Survival
          Biological Markers
      ab: Background: Acute myeloid leukemia (AML) has a heterogeneous molecular profile, clinical presentations, and response to treatments and outcomes. DNA methylation is conducted by DNA methyltransferases including DNMT3B. Poly ADP-ribose polymerase 1 belongs to a family of enzymes that mediate important cellular processes including DNA repair, transcription, and cell death/cell proliferation, and it is involved in the development, spread, treatment, and prognosis of some cancers. The objective of this study is to assess the impact of PARP1 and DNMT3B genes expression on laboratory characteristics, response to treatment and survival in Egyptian cytogenetically normal AML patients. Methods: This study included 67 Egyptian CN-AML patients in addition to 8 healthy bone marrow donors. Measurement of DNMT3B and PARP1 gene expression was done on bone marrow samples via real-time semiquantitative polymerase chain reaction. Result: Expression of both DNMT3B and PARP1 genes was significantly upregulated in AML (P =.001, P =.036, respectively). Upregulated DNMT3B was associated with higher total leukocyte count (TLC), PB, and BM blast cell%. Also, upregulated PARP1 correlated with higher TLC, PB, and BM blast cell%. High expression of both DNMT3B and PARP1 correlated with greater frequencies of FLT3-ITD. High DNMT3B expression, and combined upregulation of both PARP1 and DNMT3B genes associated significantly with ELN stratification. But no correlation was found with response (CR), overall survival (OS), disease-free survival (DFS), or event-free survival (EFS). Conclusion: Our findings highlight the importance of considering DNMT3B and PARP1 expression levels as potential prognostic biomarkers for progression and aggressiveness of CN-AML patients in AML. Assessing their expression levels could be an indicator to guide treatment decisions and potentially improve patient outcomes.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N